Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Comparison of cisplatin and lobaplatin

From: Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial

Category Cisplatin Lobaplatin
Product generation First generation Third generation
Chemical structure
Anti-tumor mechanism Forms DNA-drug adducts, resulting in DNA damage and cell apoptosis
Half-life period Over 24 h (total platinum) [33], mainly metabolized through the kidney 131 ± 15 min (free platinum) and 6.8 ± 4.3 days (total platinum) [19], mainly metabolized through the kidney
Anti-tumor spectrum Ovarian, testicular, bladder, colorectal, lung, head and neck cancer Metastatic breast cancer, chronic myelogenous leukemia, and small cell lung cancer
Side effects Nephrotoxicity, cumulative peripheral sensory neuropathy, ototoxicity, nausea and vomiting Thrombocytopenia
Additional medication Hydration for high dose No
Solvent Normal saline or glucose Glucose
Drug resistance Easy to produce Rare and no cross-resistance with cisplatin
Expense per cycle for platinum drugs ¥160.0-200.0 ($23.8-29.8) ¥2800.0-3400.0 ($417.9-507.5)